How does 309A's PE Ratio compare to its peers?

309A is expensive based on its Price-To-Earnings Ratio (78.4x) compared to the peer average (13.3x).

How does 309A's PE Ratio compare vs other companies in the JP Consumer Retailing Industry?

309A is expensive based on its Price-To-Earnings Ratio (78.4x) compared to the JP Consumer Retailing industry average (12.5x).

What is 309A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 309A's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 309A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 309A's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

COSMOS CHOUZAI PharmacyLtd TSE:309A Stock Report

Last Price

JP¥700.00

Market Cap

JP¥2.1b

7D

n/a

1Y

n/a

Updated

10 Jan, 2025

Data

Company Financials

COSMOS CHOUZAI Pharmacy Co.,Ltd.

TSE:309A Stock Report

Market Cap: JP¥2.1b

309A Stock Overview

Engages in the pharmacy management business in Japan. More details

309A fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	2/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings grew by 42.1% over the past year

Risk Analysis

Shares are highly illiquid

Less than 3 years of financial data is available

Large one-off items impacting financial results

Does not have a meaningful market cap (¥2B)

My Notes

Capture your thoughts, links and company narrative

COSMOS CHOUZAI Pharmacy Co.,Ltd. Competitors

Miahelsa Holdings

TSE:7129

JP¥2.9b

Sapporo Clinical Laboratory

TSE:9776

JP¥3.1b

Medical Ikkou GroupLtd

TSE:3353

JP¥8.2b

Satudora HoldingsLtd

TSE:3544

JP¥11.4b

Price History & Performance

Summary of share price highs, lows and changes for COSMOS CHOUZAI PharmacyLtd
Historical stock prices
Current Share Price	JP¥700.00
52 Week High	JP¥700.00
52 Week Low	JP¥700.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	309A	JP Consumer Retailing	JP Market
7D	n/a	-3.1%	-1.7%
1Y	n/a	2.9%	8.5%

Return vs Industry: Insufficient data to determine how 309A performed against the JP Consumer Retailing industry.

Return vs Market: Insufficient data to determine how 309A performed against the JP Market.

Price Volatility

Is 309A's price volatile compared to industry and market?
309A volatility
309A Average Weekly Movement	n/a
Consumer Retailing Industry Average Movement	2.8%
Market Average Movement	3.5%
10% most volatile stocks in JP Market	7.3%
10% least volatile stocks in JP Market	1.9%

Stable Share Price: 309A's share price has been volatile over the past 3 months compared to the JP market.

Volatility Over Time: Insufficient data to determine 309A's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	n/a	www.cosmos-ph.co.jp

COSMOS CHOUZAI Pharmacy Co.,Ltd. engages in the pharmacy management business in Japan. It sells medicines through stores, as well as the smartphone app, kakari; and delivers medications to patients' homes and elderly care facilities.

COSMOS CHOUZAI Pharmacy Co.,Ltd. Fundamentals Summary

How do COSMOS CHOUZAI PharmacyLtd's earnings and revenue compare to its market cap?
309A fundamental statistics
Market cap	JP¥2.12b
Earnings (TTM)	JP¥27.00m
Revenue (TTM)	JP¥6.19b

78.4x

P/E Ratio

0.3x

P/S Ratio

Is 309A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
309A income statement (TTM)
Revenue	JP¥6.19b
Cost of Revenue	JP¥3.44b
Gross Profit	JP¥2.74b
Other Expenses	JP¥2.72b
Earnings	JP¥27.00m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	8.93
Gross Margin	44.35%
Net Profit Margin	0.44%
Debt/Equity Ratio	106.5%

How did 309A perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 02:53
End of Day Share Price	2025/01/08 00:00
Earnings	2024/03/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

COSMOS CHOUZAI Pharmacy Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution